GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » EV-to-EBITDA

Simcere Pharmaceutical Group (HKSE:02096) EV-to-EBITDA : 17.23 (As of Jun. 10, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Simcere Pharmaceutical Group's enterprise value is HK$14,595 Mil. Simcere Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$847 Mil. Therefore, Simcere Pharmaceutical Group's EV-to-EBITDA for today is 17.23.

The historical rank and industry rank for Simcere Pharmaceutical Group's EV-to-EBITDA or its related term are showing as below:

HKSE:02096' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.01   Med: 13.27   Max: 26.32
Current: 17.23

During the past 7 years, the highest EV-to-EBITDA of Simcere Pharmaceutical Group was 26.32. The lowest was 8.01. And the median was 13.27.

HKSE:02096's EV-to-EBITDA is ranked worse than
60.28% of 710 companies
in the Drug Manufacturers industry
Industry Median: 14.21 vs HKSE:02096: 17.23

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-10), Simcere Pharmaceutical Group's stock price is HK$5.97. Simcere Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.285. Therefore, Simcere Pharmaceutical Group's PE Ratio for today is 20.95.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Simcere Pharmaceutical Group EV-to-EBITDA Historical Data

The historical data trend for Simcere Pharmaceutical Group's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group EV-to-EBITDA Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - 17.11 10.99 22.07 14.31

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.99 - 22.07 - 14.31

Competitive Comparison of Simcere Pharmaceutical Group's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Simcere Pharmaceutical Group's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Simcere Pharmaceutical Group's EV-to-EBITDA falls into.



Simcere Pharmaceutical Group EV-to-EBITDA Calculation

Simcere Pharmaceutical Group's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=14595.342/847.252
=17.23

Simcere Pharmaceutical Group's current Enterprise Value is HK$14,595 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$847 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Simcere Pharmaceutical Group  (HKSE:02096) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Simcere Pharmaceutical Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.97/0.285
=20.95

Simcere Pharmaceutical Group's share price for today is HK$5.97.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.285.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Simcere Pharmaceutical Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Simcere Pharmaceutical Group (HKSE:02096) Business Description

Traded in Other Exchanges
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Executives
Wang Xi 2305 Beneficiary of a trust
Ren Jinsheng 2202 Interest of your spouse
Right Wealth Holdings Limited 2501 Other
Wang Xi 2501 Other
Simcere Investments Group Limited 2501 Other
Excel Investments Group Limited 2501 Other
Simcere Pharmaceutical Holding Limited 2501 Other
Simcere Holding Limited 2501 Other
Artking Global Limited 2501 Other
Ren Zhen 2501 Other
Ren Yong 2501 Other
Ren Weidong 2501 Other
Peng Suqin 2501 Other
P&h Holdings Group Ltd. 2501 Other
Li Shimeng 2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines